Format

Send to

Choose Destination
Clin Med Rev Case Rep. 2016;3(8). pii: 125. doi: 10.23937/2378-3656/1410125. Epub 2016 Aug 16.

Hypothesizing that a Pro-Dopaminergic Regulator (KB220z Liquid Variant) can Induce "Dopamine Homeostasis" and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence.

Author information

1
Department of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, USA.
2
Department of Psychiatry & Behavioral Sciences, Keck School of Medicine of USC, USA.
3
Division of Applied Clinical Research & Education, Dominion Diagnostics, LLC, USA.
4
Division of Neuroscience-Based Therapy, Summit Estate Recovery Center, USA.
5
Division of Clinical Neurology, Path Foundation New York, USA.
6
Division of Personalized Medicine, IGENE, LLC, USA.
7
Division of Molecular Neurobiology, LaVitaRDS, USA.
8
National Institute for Holistic Studies in Addiction, USA.
9
Division of Neuroscience Research and Addiction Therapy, Shores Treatment & Recovery Center, USA.
10
Department of Clinical Psychology and Addiction, Eotvos Lorand University, Hungary.
11
Division of Clinical Addiction Medicine, Pure Recovery, USA.
12
Department of Psychiatry, Laboratory of Molecular and Functional Imaging, University at Minnesota, USA.

Abstract

In order to explore the initiation of detoxification of addictive patients to opiates/opioids (along with some other anti-withdrawal agents), we developed a protocol to be utilized in treatment centers particularly with heavily dependent opiate/opioid subjects. Out of 17 subjects, only three received Buprenorphine/Naloxone (Bup/nx) along with KB220Z. In this pilot, we first used a dose of KB220Z of 2 oz twice daily before meals along with clonidine and benzodiazepines and other anti-nausea and sleep aids including Gabapentin. The dose of KB220Z was maintained for 6 days in five individuals. In a second scenario, we utilized a higher dose of 4 oz every 6 hours, over a 6-day period. The higher dose was employed in another 12 patients. It is noteworthy that only 3 people have relapsed utilizing these two protocols during the first two weeks of the study, allowing for the remaining 82% to be maintained on KB220Z. The patients have been maintained without any additional Bup/nx for a minimum of 120 days and in one subject, 214 days. We are in the process of testing this hypothesis in multiple treatment centers across the United Sates utilizing data from the Clinical opiate Withdrawal Scale (COWS) pre and post KB220Z. We are in the process of testing this hypothesis in multiple treatment centers across the United Sates. While this does not constitute an acceptable controlled experiment, it does provide some preliminary evidence that agrees with an earlier study. Moreover, because of the utilization of standard detoxifying agents in this detoxification protocol, we cannot make any inference to KB220Z's effects. However, out of 17 subjects, only three required Bup/nx suggesting an interesting finding. If further confirmed in larger studies, the utilization for opiate/opioid detoxification may provide a novel way to eliminate the need for addictive opioids during withdrawal and detoxification. This paradigm shift may translate to a reduction in utilizing powerful and addictive opioids like buprenorphine and methadone (especially in these patients at high genetic risk for addiction) as not only detoxifying agents, but also maintenance drugs. While extensive research is required, this pilot paves the way for future investigations that could assist in the reduction of addictive opiate/opioid use and mortalities amongst both the young and old in America.

KEYWORDS:

Bup/nx; Detoxification; KB220Z liquid variant; Opiate/Opioid addiction; Withdrawal

Conflict of interest statement

Conflict of Interest Kenneth Blum, PhD, is the inventor of KB220Z and his company Synaptamine holds a number of U.S. and foreign patents that have been licensed to LaVita RDS. Drs. Blum (Chairman), Febo and Badgaiyan is on the Scientific Advisory Board of LaVita RDS. There are no other conflicts of interest to report.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center